ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Charity Puts Drug In The Clinic

by Lisa M. Jarvis
September 20, 2010 | APPEARED IN VOLUME 88, ISSUE 38

Cancer Research UK will conduct early trials for cancer of a compound owned by AstraZeneca. The nonprofit expects to start the Phase I/II trial of AZD-3965, which blocks monocarboxylate transporter 1, a key player in cell metabolism, in 2011. If the results are promising, AstraZeneca can choose to take on development of the compound. But if AstraZeneca declines to pursue the drug, the rights revert to Cancer Research UK. AZD-3965 is the second compound to enter clinical trials as part of the charity’s initiative to push forward cancer drug candidates that had stalled in development. This summer, it started a Phase I trial of GlaxoSmithKline’s aurora kinase inhibitor GSK1070916.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment